Inventor
KATZ DAVID H
24 patents
⚠️ This page may combine multiple inventors who share the name “KATZ DAVID H”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
SCRIPPS CLINIC RES
7 patentsUS4191668AMar 4, 1980
Induction of immunological tolerance
SCRIPPS CLINIC RES52 citations96
US4220565ASep 2, 1980
Immunochemical conjugates: method and composition
SCRIPPS CLINIC RES43 citations92
US4388441AJun 14, 1983
Induction of immunological tolerance
SCRIPPS CLINIC RES27 citations82
US4253996AMar 3, 1981
Immunochemical conjugates: method and composition
SCRIPPS CLINIC RES21 citations82
US4222907ASep 16, 1980
Induction of immunological tolerance
SCRIPPS CLINIC RES22 citations82
US4276206AJun 30, 1981
Immunochemical conjugates: method and composition
SCRIPPS CLINIC RES19 citations74
US4253995AMar 3, 1981
Immunochemical conjugates: method and composition
SCRIPPS CLINIC RES13 citations74
LIDAK PHARMACEUTICALS
5 patentsUS5534554AJul 9, 1996
Sucrose ester-C20 to C28 alcohol formulations
LIDAK PHARMACEUTICALS54 citations94
US5166219ANov 24, 1992
Systemic anti-inflammatory treatment
LIDAK PHARMACEUTICALS24 citations92
US5948822ASep 7, 1999
Treatment of hyperproliferative skin disorders with C18 to C26 alphatic alcohols
LIDAK PHARMACEUTICALS16 citations80
US5071879ADec 10, 1991
Systemic antiviral treatment
LIDAK PHARMACEUTICALS16 citations73
US5070107ADec 3, 1991
Systemic antiviral treatment
LIDAK PHARMACEUTICALS11 citations73
AVANIR PHARMACEUTICALS
4 patentsUS5952392ASep 14, 1999
Long-chain alcohols, alkanes, fatty acids and amides in the treatment of burns and viral inhibition
AVANIR PHARMACEUTICALS144 citations97
US7091190B2Aug 15, 2006
Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
AVANIR PHARMACEUTICALS7 citations72
US6440980B1Aug 27, 2002
Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
AVANIR PHARMACEUTICALS10 citations72
US6313179B1Nov 6, 2001
Treatment of hyperproliferative skin disorders with C18 to C20 aliphatic alcohols
AVANIR PHARMACEUTICALS9 citations72